Munich - Delayed Quote • EUR NovoCure Ltd (038.MU) Follow Add holdings 15.77 +0.04 +(0.25%) As of 8:02:28 AM GMT+2. Market Open. Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 038.MU 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 038.MU View More All News Press Releases SEC Filings The Next Frontier to Treat Cancer: Electricity Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? Why NovoCure Stock Skyrocketed This Week Why NovoCure Stock Leaped 4% Higher Today NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates NovoCure: Q1 Earnings Snapshot Novocure Reports First Quarter 2025 Financial Results Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting Novocure’s device for metastatic NSCLC treatment gains CE Mark